Skip to main content
Erschienen in: ästhetische dermatologie & kosmetologie 6/2018

05.12.2018 | Körperkonturierung | fortbildung

Körperformung ohne Operation

Nicht invasive Verfahren zur Lipolyse

verfasst von: Dr. med. Jennifer Quist, Sven R. Quist

Erschienen in: ästhetische dermatologie & kosmetologie | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Body Contouring ohne Skalpell umfasst neue Behandlungsformen in der Ästhetischen Medizin, die sich hoher Nachfrage erfreuen. Insbesondere Patienten mit Bedenken gegenüber operativen plastisch-chirurgischen Verfahren oder Kontraindikationen zum operativen Eingriff wählen nicht operative Methoden. Neben den bisher etablierten Verfahren existiert eine ganze Reihe neuer Optionen, mit denen die Körperformung oder besser gesagt die Fettreduktion, die dann eine Körperformung vornimmt, gelingt. Hier sollen verschiedene nicht invasive Methoden beschrieben und gegeneinander abgewogen werden.
Literatur
1.
Zurück zum Zitat Rzepecki AK et al. Update on noninvasive body contouring techniques. Cutis. 2018; 101: 285–8 PubMed Rzepecki AK et al. Update on noninvasive body contouring techniques. Cutis. 2018; 101: 285–8 PubMed
2.
Zurück zum Zitat Decorato JW et al. Subcutaneous adipose tissue response to a non-invasive hyperthermic treatment using a 1,060 nm laser. Lasers Surg Med. 2017; 49: 480–9 CrossRef Decorato JW et al. Subcutaneous adipose tissue response to a non-invasive hyperthermic treatment using a 1,060 nm laser. Lasers Surg Med. 2017; 49: 480–9 CrossRef
3.
Zurück zum Zitat Schilling L et al. 1060 nm Diode Hyperthermic Laser Lipolysis:The Latest in Non-Invasive Body Contouring. J Drugs Dermatol. 2017; 16: 48–52 PubMed Schilling L et al. 1060 nm Diode Hyperthermic Laser Lipolysis:The Latest in Non-Invasive Body Contouring. J Drugs Dermatol. 2017; 16: 48–52 PubMed
4.
Zurück zum Zitat Bass LS, Doherty ST. Safety and Efficacy of a Non-Invasive 1060 nm Diode Laser for Fat Reduction of the Abdomen. J Drugs Dermatol. 2018; 17: 106–12 PubMed Bass LS, Doherty ST. Safety and Efficacy of a Non-Invasive 1060 nm Diode Laser for Fat Reduction of the Abdomen. J Drugs Dermatol. 2018; 17: 106–12 PubMed
5.
Zurück zum Zitat Sweeney DL et al. Combined Hyperthermic 1060nm Diode Laser Lipolysis With Topical Skin Tightening Treatment: Case Series. J Drugs Dermatol. 2018; 17: 780–5 PubMed Sweeney DL et al. Combined Hyperthermic 1060nm Diode Laser Lipolysis With Topical Skin Tightening Treatment: Case Series. J Drugs Dermatol. 2018; 17: 780–5 PubMed
6.
Zurück zum Zitat Jackson RF et al. Low-level laser therapy as a non-invasive approach for body contouring: a randomized, controlled study. Lasers Surg Med. 2009; 41: 799–809 CrossRef Jackson RF et al. Low-level laser therapy as a non-invasive approach for body contouring: a randomized, controlled study. Lasers Surg Med. 2009; 41: 799–809 CrossRef
7.
Zurück zum Zitat Jankowski M et al. Low-level laser therapy (LLLT) does not reduce subcutaneous adipose tissue by local adipocyte injury but rather by modulation of systemic lipid metabolism. Lasers Med Sci. 2017; 32: 475–9 CrossRef Jankowski M et al. Low-level laser therapy (LLLT) does not reduce subcutaneous adipose tissue by local adipocyte injury but rather by modulation of systemic lipid metabolism. Lasers Med Sci. 2017; 32: 475–9 CrossRef
8.
Zurück zum Zitat Avci P et al. Low-level laser therapy for fat layer reduction: a comprehensive review. Lasers Surg Med. 2013; 45: 349–57 CrossRef Avci P et al. Low-level laser therapy for fat layer reduction: a comprehensive review. Lasers Surg Med. 2013; 45: 349–57 CrossRef
9.
Zurück zum Zitat Zelickson BD et al. Cryolipolysis for safe and effective inner thigh fat reduction. Lasers Surg Med. 2015; 47: 120–7 CrossRef Zelickson BD et al. Cryolipolysis for safe and effective inner thigh fat reduction. Lasers Surg Med. 2015; 47: 120–7 CrossRef
10.
Zurück zum Zitat Bernstein EF, Bloom JD. Safety and Efficacy of Bilateral Submental Cryolipolysis With Quantified 3-Dimensional Imaging of Fat Reduction and Skin Tightening. JAMA Facial Plast Surg. 2017; 19: 350–7 CrossRef Bernstein EF, Bloom JD. Safety and Efficacy of Bilateral Submental Cryolipolysis With Quantified 3-Dimensional Imaging of Fat Reduction and Skin Tightening. JAMA Facial Plast Surg. 2017; 19: 350–7 CrossRef
11.
Zurück zum Zitat Kilmer SL et al. Safety and efficacy of cryolipolysis for non-invasive reduction of submental fat. Lasers Surg Med. 2016; 48: 3–13 CrossRef Kilmer SL et al. Safety and efficacy of cryolipolysis for non-invasive reduction of submental fat. Lasers Surg Med. 2016; 48: 3–13 CrossRef
12.
Zurück zum Zitat Ho D, Jagdeo J. A Systematic Review of Paradoxical Adipose Hyperplasia (PAH) Post-Cryolipolysis. J Drugs Dermatol. 2017; 16: 62–7 PubMed Ho D, Jagdeo J. A Systematic Review of Paradoxical Adipose Hyperplasia (PAH) Post-Cryolipolysis. J Drugs Dermatol. 2017; 16: 62–7 PubMed
13.
Zurück zum Zitat Kilmer SL. Prototype CoolCup cryolipolysis applicator with over 40 % reduced treatment time demonstrates equivalent safety and efficacy with greater patient preference. Lasers Surg Med. 2017; 49: 63–8 CrossRef Kilmer SL. Prototype CoolCup cryolipolysis applicator with over 40 % reduced treatment time demonstrates equivalent safety and efficacy with greater patient preference. Lasers Surg Med. 2017; 49: 63–8 CrossRef
14.
Zurück zum Zitat Klein KB et al. Multiple same day cryolipolysis treatments for the reduction of subcutaneous fat are safe and do not affect serum lipid levels or liver function tests. Lasers Surg Med. 2017; 49: 640–4 CrossRef Klein KB et al. Multiple same day cryolipolysis treatments for the reduction of subcutaneous fat are safe and do not affect serum lipid levels or liver function tests. Lasers Surg Med. 2017; 49: 640–4 CrossRef
15.
Zurück zum Zitat Ingargiola MJ et al. Cryolipolysis for fat reduction and body contouring: safety and efficacy of current treatment paradigms. Plast Reconstr Surg. 2015; 135: 1581–90 CrossRef Ingargiola MJ et al. Cryolipolysis for fat reduction and body contouring: safety and efficacy of current treatment paradigms. Plast Reconstr Surg. 2015; 135: 1581–90 CrossRef
16.
Zurück zum Zitat Downie J, Kaspar M. Contactless Abdominal Fat Reduction With Selective RF Evaluated by Magnetic Resonance Imaging (MRI): Case Study. J Drugs Dermatol. 2016; 15: 491–5 PubMed Downie J, Kaspar M. Contactless Abdominal Fat Reduction With Selective RF Evaluated by Magnetic Resonance Imaging (MRI): Case Study. J Drugs Dermatol. 2016; 15: 491–5 PubMed
17.
Zurück zum Zitat Gold MH et al. A randomized, controlled multicenter study evaluating focused ultrasound treatment for fat reduction in the flanks. J Cosmet Laser Ther. 2018; 13: 1–5 Gold MH et al. A randomized, controlled multicenter study evaluating focused ultrasound treatment for fat reduction in the flanks. J Cosmet Laser Ther. 2018; 13: 1–5
18.
Zurück zum Zitat Guth F et al. Immediate effect and safety of HIFU single treatment for male subcutaneous fat reduction. J Cosmet Dermatol. 2018; 17: 385–9 CrossRef Guth F et al. Immediate effect and safety of HIFU single treatment for male subcutaneous fat reduction. J Cosmet Dermatol. 2018; 17: 385–9 CrossRef
20.
Zurück zum Zitat Jacob CI, Paskova K. Safety and efficacy of a novel high-intensity focused electromagnetic technology device for noninvasive abdominal body shaping. J Cosmet Dermatol. 2018; 17: 783–7 CrossRef Jacob CI, Paskova K. Safety and efficacy of a novel high-intensity focused electromagnetic technology device for noninvasive abdominal body shaping. J Cosmet Dermatol. 2018; 17: 783–7 CrossRef
21.
Zurück zum Zitat Ascher B et al. Efficacy, patient-reported outcomes and safety profile of ATX-101 (deoxycholic acid), an injectable drug for the reduction of unwanted submental fat: results from a phase III, randomized, placebocontrolled study. J Eur Acad Dermatol Venereol. 2014; 28: 1707–15 CrossRef Ascher B et al. Efficacy, patient-reported outcomes and safety profile of ATX-101 (deoxycholic acid), an injectable drug for the reduction of unwanted submental fat: results from a phase III, randomized, placebocontrolled study. J Eur Acad Dermatol Venereol. 2014; 28: 1707–15 CrossRef
22.
Zurück zum Zitat Rzany B et al. Reduction of unwanted submental fat with ATX-101 (deoxycholic acid), an adipocytolytic injectable treatment: results from a phase III, randomized, placebo-controlled study. Br J Dermatol. 2014; 170: 445–53 CrossRef Rzany B et al. Reduction of unwanted submental fat with ATX-101 (deoxycholic acid), an adipocytolytic injectable treatment: results from a phase III, randomized, placebo-controlled study. Br J Dermatol. 2014; 170: 445–53 CrossRef
23.
Zurück zum Zitat Ascher B et al. ATX-101 (deoxycholic acid injection) for reduction of submental fat. Expert Rev Clin Pharmacol. 2016; 9: 1131–43 CrossRef Ascher B et al. ATX-101 (deoxycholic acid injection) for reduction of submental fat. Expert Rev Clin Pharmacol. 2016; 9: 1131–43 CrossRef
24.
Zurück zum Zitat Dover JS et al. Management of Patient Experience With ATX-101 (Deoxycholic Acid Injection) for Reduction of Submental Fat. Dermatol Surg. 2016; 42 Suppl 1: S288–99 CrossRef Dover JS et al. Management of Patient Experience With ATX-101 (Deoxycholic Acid Injection) for Reduction of Submental Fat. Dermatol Surg. 2016; 42 Suppl 1: S288–99 CrossRef
25.
Zurück zum Zitat Wollina U, Goldman A. ATX-101 for reduction of submental fat. Expert Opin Pharmacother. 2015; 16: 755–62 CrossRef Wollina U, Goldman A. ATX-101 for reduction of submental fat. Expert Opin Pharmacother. 2015; 16: 755–62 CrossRef
Metadaten
Titel
Körperformung ohne Operation
Nicht invasive Verfahren zur Lipolyse
verfasst von
Dr. med. Jennifer Quist
Sven R. Quist
Publikationsdatum
05.12.2018
Verlag
Springer Medizin
Erschienen in
ästhetische dermatologie & kosmetologie / Ausgabe 6/2018
Print ISSN: 1867-481X
Elektronische ISSN: 2198-6517
DOI
https://doi.org/10.1007/s12634-018-5704-3

Weitere Artikel der Ausgabe 6/2018

ästhetische dermatologie & kosmetologie 6/2018 Zur Ausgabe

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Passend zum Thema

Deucravacitinib – neuer First-in-Class-Wirkstoff bei Plaque-Psoriasis

Deucravacitinib – neuer First-in-Class-Wirkstoff bei Plaque-Psoriasis

Deucravacitinib von Bristol Myers Squibb ist ein selektiver, allosterischer Tyrosinkinase-2-Inhibitor und der erste Vertreter dieser neuen Klasse niedermolekularer Wirkstoffe. Eingesetzt wird das oral einzunehmende Medikament zur systemischen Behandlung Erwachsener mit mittelschwerer bis schwerer Plaque-Psoriasis.